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Abstract
Background: Sexual dysfunction is frequent in patients with schizophrenia, it is reported as one of the most distress-
ing antipsychotic’s adverse effects and it is directly related to treatment compliance. Objectives: a) to evaluate the 
accuracy of the Arizona Sexual Experience Scale (ASEX) to identify sexual dysfunction; b) to assess the frequency 
of sexual dysfunction in a sample of outpatients with schizophrenia and schizoaffective disorder under antipsychotic 
therapy; and c) to investigate the effect of different antipsychotics on sexual function. Method: Outpatients with 
schizophrenia or schizoaffective disorder were asked to fulfill both the ASEX and the Dickson Glazer Scale for the 
Assessment of Sexual Functioning Inventory (DGSFi) at a single interview. Results: 137 patients were interwied. 
The sensitivity and specificity of the ASEX in relation to DGSFi were: 80.8%, (95% CI = 70.0%-88.5%) and 88.1% (95% 
CI = 76.5%-94.7%), and the misclassification rate was 9.5%. The ROC curve comparing the ASEX and the DGSFi scores 
revealed a value of 0.93 (CI = 0.879-0.970), with the optimum cut-off point of ASEX being 14/15. Sexual dysfunction 
measured was higher in females (79.2%) than in males (33.3%) (χ2 = 27.41, d.f. = 1, p < 0.001). Discussion: Patients 
under antipsychotic treatment showed a high level of sexual complaints, and the ASEX proved to be an accurate instru-
ment to identify sexual dysfunction in an outpatient sample of patients with schizophrenia spectrum. Females showed 
a higher frequency of sexual dysfunctions and sexual drive and ability to reach orgasm were the most affected areas. 
The use of antipsychotics, especially the combinations, was more likely to impair sexual functioning. 
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Resumo
Contexto: A disfunção sexual é frequente entre pacientes com esquizofrenia, sendo relatada como um dos mais in-
cômodos efeitos adversos dos antipsicóticos e está diretamente relacionada com a adesão ao tratamento. Objetivos: 
a) avaliar a acurácia da Escala de Experiência Sexual do Arizona (ASEX) para identificar disfunção sexual; b) avaliar 
a frequência da disfunção sexual em uma amostra de pacientes do espectro da esquizofrenia em tratamento com 
antipsicóticos; e c) investigar o efeito dos diferentes antipsicóticos na função sexual. Método: Foram entrevistados 
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Introduction
Long term treatment is indicated for all patients with 
schizophrenia1. Antipsychotic drugs can be of great 
benefit for a wide range of psychotic disorders, although 
treatment can be associated with potential and unplea-
sant adverse effects2. Antipsychotic drugs may restore 
sexual desire lost for patients with schizophrenia, but 
they can also impair the patient’s sexual performance3-5. 
Antipsychotics can cause sexual dysfunction through 
multiple mechanisms, including sedation, hyperprolac-
tinaemia (wich can cause sexual dysfunction directly 
and indirectly by causing secondary hypogonadism) and 
antagonism of a-adrenergic, dopaminergic, histaminic 
and muscarinic receptors2. Moreover, there are many 
other factors that may cause sexual problems for patients 
with schizophrenia, including concomitant medications, 
the effect of the disease itself, comorbidity with other 
psychiatric disorders and various endocrine, vascular 
or genitourinary diseases6. Negative symptoms of the 
disorder, such as anhedonia, avolition and blunted affect 
related to hypodopaminergic activity in the frontal cor-
tex, severely harm the ability to enjoy sexual life. These 
patients face difficulties in establishing relationships 
due to recurrent psychotic episodes, obesity and low 
self-steem7.
It is noteworthy that a recent study conducted by 
Plevin et al.8 reported that 73% of men presented com-
plaints in at least one area of antipsychotic-induced 
sexual dysfunction: a) erectile, ejaculatory, and orgasmic 
dysfunction9-16 b) low sexual desire11,13-16 and c) pria-
pism12. Although fewer studies have been conducted 
with females, there is evidence of sexual dysfunctions 
in the following areas: a) lack of orgasm11,13,17,18 b) low 
lubrification13,19 c) loss of libido14,19 and d) amenorrhea11. 
Sexual dysfunctions induced by antipsychotic treatment 
can be responsible for non-adherence to treatment20 
and non compliance is one of the main obstacles to an 
adequate control of the symptoms present in patients 
with schizophrenia2. Moreover, sexual dysfunction is 
rated as one of the most distressing adverse effects of 
antipsychotic treatment22,23 and experienced by patients 
as significantly more distressing than sedation, or ex-
trapyramidal side effects22. 
At present, there are three scales available to asses 
sexual dysfunctions in patients under antipsychotic 
treatment: a) the Dickson and Glazer Scale for the As-
sessment of Sexual Functioning Inventory (DGSFi)24; b) 
the Arizona Sexual Experience Scale (ASEX)25, c) the 
Psychotropic-Related Sexual Dysfunction (PRSexDQ-
SALSEX)26. Unlike the more traditional and lengthy 
scales for assessing sexual dysfunctions, the ASEX 
can be completed in approximately 5 minutes27 and it 
was designed to be self- or clinician-administered. In 
addition, the ASEX questionnaire can be used for hete-
rossexual and homossexual populations, as well as for 
those without sexual partners28.
Antipsychotic-induced sexual dysfunctions are po-
orly recognized, and not properly investigated by most 
clinicians29. Thus, it is very important to have accurate 
tools to aid clinicians in the diagnosis of antipsychotic-
induced sexual dysfunctions28. The main aims of this 
paper are threefold: a) to evaluate the accuracy of the 
ASEX to identify sexual dysfunction; b) to assess the fre-
quency of sexual dysfunction in a sample of outpatients 
with schizophrenia and schizoaffective disorder under 
antipsychotic therapy; and c) to investigate the effect of 
different antipsychotics on sexual function.
Methods
A cross-sectional study of sexual function was conducted 
with 1-year consecutive outpatients from the Schizo-
phrenia Program of the Universidade Federal de São 
Paulo (Proesq), from February 2007 to January 2008. 
The study was submitted and approved by the Ethics 
Committee of the Universidade Federal de São Paulo, 
and participants signed a written informed consent to 
pacientes ambulatoriais com esquizofrenia ou transtorno esquizoafetivo por meio dos questionários ASEX e Escala 
Dickson-Glazer (DGSFi) para avaliação do funcionamento sexual, em uma única entrevista. Resultados: 137 pa-
cientes foram entrevistados. A sensibilidade e a especificidade da ASEX em relação à DGSFi foram: 80,8% (95% 
IC = 70,0%-88,5%) e 88,1% (95% IC = 76,5%-94,7%), e a taxa de classificação incorreta foi 9,5%. A curva ROC comparando 
a pontuação da ASEX e a DGSFi revelou valor de 0,93 (IC = 0,879-0,970) com o ponto de corte da ASEX encontrado 
sendo 14/15. A disfunção sexual foi mais alta entre as mulheres (79,2%) do que nos homens (33,3%) (χ2 = 27,41, gl = 1, 
p < 0,001). Conclusão: Os pacientes em tratamento com antipsicóticos mostraram alta frequência de queixas sexuais e 
a ASEX provou ser um instrumento eficaz para identificar disfunção sexual em amostra de pacientes ambulatoriais do 
espectro da esquizofrenia. As mulheres mostraram frequência mais alta de disfunção, e o desejo sexual e a habilidade 
para alcançar orgasmo foram as áreas mais afetadas. O uso de antipsicóticos, principalmente o uso de combinações, 
foi associado com a piora do funcionamento sexual.
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participate. Eligible subjects recruited were stabilized 
outpatients who met DSM-IV criteria for schizophrenia 
and schizoaffective disorder under antipsychotic thera-
py for at least four weeks. The patients were currently 
receiving a fixed dose of a first- or second-generation an-
tipsychotic (risperidone was analyzed separately since it 
is an antipsychotic that frequently causes hyperprolacti-
naemia), or a combination of first- and second-generation 
antipsychotics, or a combination of antipsychotics and 
antidepressants. Patients consecutively attending the 
outpatient clinic were asked to fulfill a questionnaire 
comprising information on social and demographic 
characteristics, clinical symptoms, pharmacologic 
treatment, substance use disorders, sexual function, 
presence of partner, and time of disease onset, followed 
by the application of the ASEX and the DGSFi. 
Instruments
The DGSFi was developed by Ruth Dickson and 
Willian Glazer in the University of Calgary, Canada, 
to assess sexual dysfunctions in patients suffering 
from schizophrenia spectrum disorders. It is a com-
puterized assessment, categorical and qualitative, of 
sexual functioning and was developed to be easy for 
the researcher to obtain detailed information redu-
cing embarrassment and discomfort for patients. The 
DGSFi is a computerized self-report questionnaire of 
sexual functioning with parallel versions developed for 
males (32 questions) and females (41 questions). It is a 
multiple choice questionnaire aiming to assess sexual 
activity frequency, desire, arousal, and orgasm for both 
solitary and partner sexual activities and perceptions 
of medication side effects for the prior 2 weeks24. A 
Brazilian version of the DGSFi was adapted and used 
by Costa et al.30 to compare the frequency of sexual 
dysfunction between first-generation antipsychotic 
treatment and olanzapine. 
 The ASEX was developed by McGahuey et al. in the 
University of Arizona in response to the need for eva-
luating psychotropic drug-induced sexual dysfunction. 
Initially, the scale was tested to assess sexual dysfunction 
among selective serotonin reuptake inhibitor (SSRI)-
treated subjects25 and end-stage renal disease31. Byerly et 
al. tested the psychometric properties of ASEX in patients 
with schizophrenia and schizoaffective disorder and de-
monstrated that ASEX represents an easy-to-administer 
tool for assessing sexual dysfunction in this population28. 
The ASEX is a brief 5-item questionnaire designed to me-
asure sexual functioning in the following domains: sexual 
drive, arousal, penile erection/vaginal lubrification, ability 
to reach orgasm, and satisfaction with orgasm over the 
past week25. Items are rated on a 6-point scale ranging 
from 1(hyperfunction) through to 6 (hypofunction), pro-
viding a total score range between 5 and 30. A total score 
> 18, or a score ≥ 5 (very difficult) on any single item or 
any three items with individual scores ≥ 4 is indicative of 
clinically significant sexual dysfunction. 
Results
The sociodemographic and clinical characteristics of 
the sample can be seen in table 1. The sample was com-
prised of 137 patients, with an excess of males (61.3%). 
The mean age of the sample was 37 ± 10.3 years. Most 
patients were Caucasians (62.0%), with a mean of 11.6 ± 
4.1 years of schooling. Most patients were unemployed 
(78.1%). Most patients were single (82.6% men and 78.4% 
women), and only few patients (2.9%) were married (3.5% 
of men and 2% of women), or had a stable partner (9.3% 
of men and 3.9% of women). The mean duration of illness 
was 14.4 ± 9 years, with no difference between sexes. 
Patients on second-generation antipsychotics (without 
risperidone) corresponded to 46.7% (n = 64) of the 
sample and patients on first-generation antipsychotics 
corresponded to 16.1% (n = 22). Risperidone was used 
by 14 patients (10.2%). Combination of antipsychotics 
was taken by 13 patients (9.5%) and combined antip-
sychotics and antidepressants were prescribed to 24 
patients (17.5%). 
All the patients (n = 137) filled both questionnai-
res (ASEX and DGSFi). The internal consistency of 
the ASEX was estimated by means of the Cronbach’s 
coefficient (=0.81), and mean Pearson’s correlation 
for the five ASEX items was 0.47. Table 2 displays the 
distribution of the ASEX scores against the DGSFi 
scores. As it can be seen in Table II, sensitivity was 
80.8% (95% CI = 70-88.5), specificity was 88.1%(95% 
CI = 76.5-94.7), predictive positive value (PPV) was 90% 
(95% CI = 79.9-95.5), and negative predictive value (NPV) 
was 77.6% (95% CI = 65.5-86.5). The misclassification 
rate was 9.5%. As it can be seen in figure 1 the compari-
son between the ASEX and the DGSFi scores resulted 
in an area under the curve value of 0.93 ± 0.021 (95% 
CI = 0.88-0.97, p = 0.0001). The ASEX cut-off point for 
sexual dysfunction was found to be 14/15. 
Table 3 displays the distribution of penile erection 
or vaginal lubrification dysfunction according to type 
of treatment. The highest percentage of dysfunction 
occurred for patients under the combination of antip-
sychotics (61.5%), followed by combined antipsychotics 
and antidepressants (50%). Patients under second-
generation antipsychotics presented a higher probability 
of dysfunction (28.1%) than those under first-generation 
antipsychotics (13.6%), the difference being statistically 
significant (Fisher’s exact test, p = 0.00108). 
For the ASEX items sexual drive, arousal, and sa-
tisfaction, there were no statistical differences across 
treatments. 
Table 4 displays the distribution of sexual dysfunction 
between genders across the pharmacological interven-
tions. Sexual dysfunction measured by ASEX was high-
er in females (79.2%) than in males (33.3%), and the dif-
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Table 1. The sociodemographic and clinical characteristics of the schizophrenia spectrum outpatients. 
Male Female Total  p Value
Gender (n e %) 84 (61.3%) 53 (38.7%) 137 < 0.001
Age, years (mean, SD) 36.7 (SD = 9.6) 37.5 (SD = 11.4) 37.0 (SD = 10.3) 0.663* t
Marital Status (n e %)
Married
Stable Partner
Single
Widow
Divorced
3 (3.5%)
8 (9.3%)
69 (82.6%)
–
4 (4.7%)
1 (2.0%)
2 (3.9%)
42 (78.4%)
2 (3.9%)
6 (11.8%)
4 (2.9%)
10 (7.3%)
111 (81.0%)
2 (1.5%)
10 (7.3%)
0.144† f
Race/Ethnicity (n e %)
Caucasians
Asians
Africans
Mestizos
Others
55 (65.5%)
10 (11.9%)
2 (2.4%)
9 (10.7%)
8 (9.5%)
30 (56.6%)
11 (20.8%)
2 (3.8%)
5 (9.4%)
5 (9.4%)
85 (62.0%)
21 (15.3%)
4 (2.9%)
14 (10.2%)
13 (9.5%)
0.673‡ q
Mean years of schooling 11.8 (SD = 4.1) 11.4 (SD = 4.0) 11.6 (SD = 4.1) 0.632* t
Employment Status 
Unemployed
Employed or Studying
65 (77.4%)
19 (22.6%)
43 (81.1%)
10 (18.9%)
108 (78.8%)
29 (21.2%)
0.601
‡
 q
Illness Duration (years, mean, SD) 14.4 (SD = 9.1) 14.0 (SD = 8.8) 14.4 (SD = 9.0) 0.779* t
Medications 
First Generation
Second Generation
First + Second Generation
Risperidone
Antipsychotics + antidepressants
11 (13.1%)
46 (54.8%)
5 (6.0%)
10 (11.9%)
12 (14.3%)
11 (20.8%)
18 (34.0%)
8 (15.1%)
4 (7.5%)
12 (22.6%)
22 (16.1%)
64 (46.7%)
13 (9.5%)
14 (10.2%)
24 (17.5%)
0.062
‡
 q
Number of admissions 3.6 (SD = 11.3) 2.2 (SD = 2.3) 2.4 (SD = 3.5) 0.468§ u
Sexual Dysfunction 28 (33.3%) 42 (79.2%) p < 0.001‡ q
* Student’s t test; † Fisher’s exact test; ‡ Chi-square test; § Mann-Whitney test.
Table 2. The validity coefficients comparing the ASEX scores against the DGSFi scores.
DGSFi Dysfunction DGSFi No dysfunction Total
ASEX 
Dysfunction
63 7 70 PPV = 90.0 (CI = 79.9-95.5)
ASEX 
No dysfunction
15 52 67 NPV = 77.6 (CI = 65.5-86.5)
Total 78 59 n = 137
Sensitivity = 80.8 (CI = 70-88.5) Specificity = 88.1 (CI = 76.5-94.7)
ASEX score 20.56 ± 4.85 11.16 ± 3.72 15.96 ± 6.39 p = 0.001 (Mann Whitney test)
Table 3. The distribution of sexual dysfunction given by the ASEX questionnaire according to the pharmacological treatment.
Medication Penis erec/Vaginal lub (male and female)
No dysfunction  
N %
With dysfunction 
N %
First-generation Antipsychotics 19 (86.4%) 3 (13.6%)
Second-generation Antipsychotics 46 (71.9%) 18 (28.1%)
Risperidone 11 (78.6%) 3 (21.4%)
Combination of antipsychotics 5 (38.5%) 8 (61.5%)
Antipsychotics and Antidepressants 12 (50%) 12 (50%)
Fisher ‘s exact test = p = 0.0108
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being statistically significant (Fisher’s exact test, 
p = 0.0131). Moreover, females had higher probability 
of dysfunction in reaching orgasm than males when 
under pharmacological inter ventions, the dif fer-
ence being statistically significant (Fisher’s exact 
test, p = 0.0225). The distribution of sexual dysfunc-
tion by gender in the ASEX scores can be seen in 
table 5. Sexual functions as sexual drive (χ2 = 19.38, 
d.f. = 1, p < 0.001), sexual arousal (χ2 = 14.29, d.f. = 1, 
p < 0.001), orgasm (χ2 = 26.17, d.f. = 1, p < 0.001) 
and satisfaction with orgasm (χ2 = 12.26, d.f. = 1, 
p < 0.001) occurred in higher frequency in females 
than in males, and these differences were all statisti-
cally significant.
Figure 1. The ROC curve and 95% confidence interval, comparing the ASEX 
and the DGSFi scores.
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Table 5. The ASEX gender distribution of sexual 
dysfunction in an outpatient sample of patients of the 
schizophrenia spectrum.
Male Female Total p-value
n % n % n %
Sexual drive 22 26.2 34 64.2 56 40.9 < 0.001
Sexual arousal 22 26.2 31 58.5 53 38.7 < 0.001
Penis erection/
Vaginal 
lubrification 
20 23.8 24 45.3 44 32.1 0.009
Orgasm 20 23.8 36 67.9 56 40.9 < 0.001
Satisfaction with 
orgasm 16 19.0 25 47.2 41 29.9 < 0.001
Table 4. The ASEX gender sexual distribution across pharmacological interventions in an outpatient sample of patients of 
the schizophrenia spectrum.
Second 
generation
First 
generation
Risper. First + second 
generation
Antipsyc + 
Antidep
p-value*
Female
Male
n = 18
n = 46
n = 11
n = 11
n = 4
n = 10
n = 8
n = 5
n = 12
n = 12
Sexual Drive
Female
Male
12 (66.7%)
13 (28.3%)
6 (54.6%)
2 (18.2%)
–
3 (30.0%)
8 (100.0%)
1 (20.0%)
8 (66.7%)
3 (25.0%)
0.0131
0.9821
Arousal
Female
Male
11 (61.1%)
13 (28.3%)
5 (45.5%)
1 (9.1%)
1 (25.0%)
4 (40.0%)
6 (75.0%)
1 (20.0%)
8 (66.7%)
3 (25.0%)
0.4585
0.6044
Penis erec/Vaginal lubr
Female
Male
6 (33.3%)
12 (26.1%)
3 (27.3%)
–
1 (25.0%)
2 (20.0%)
5 (62.5%)
3 (60.0%)
9 (75.0%)
3 (25.0%)
0.0802
0.1041
Orgasm
Female
Male
12 (66.7%)
13 (28.3%)
5 (45.5%)
2 (18.2%)
1 (25.0%)
3 (30.0%)
8 (100.0%)
1 (20.0%)
10 (83.3%)
1 (8.3%)
0.0225
0.6664
Satisfaction
Female
Male
10 (55.6%)
10 (21.7%)
3 (27.3%)
–
1 (25.0%)
4 (40.0%)
5 (62.5%)
–
6 (50.0%)
2 (16.7%)
0.4573
0.1578
* Fisher’s exact test.
ference was statistically significant (chi-square = 27.41, 
d.f. = 1, p < 0,001). The mean ASEX scores for females 
(19.53 ± 5,69) was higher than those found for males 
(13.71 ± 5.78), and this dif ference was statistically 
significant (t = 5.77, d.f. = 1, p < 0,001). Females were 
more likely to have higher difficulty in sexual drive 
than males when using medications, the difference 
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Discussion
The ASEX questionnaire proved to be an accurate ins-
trument to identify sexual dysfunction when compared 
to the validity of the DGSFi questionnaire. Sensitivity 
and specificity were fairly high at a c.o. p. = 14/15. It is 
a friendly self-administered questionnaire, which takes 
a few minutes to be completed and is appropriate for 
individuals with or without stable sexual partners and 
for heterossexual or homossexual patients27,28. It was 
decided to use the DGSFi questionnaire as a gold stan-
dard because it was the only one adapted for a Brazilian 
social and cultural context. The DGSFi was applied by 
Costa et al. 30 to compare the frequency of sexual dys-
function among patients with schizophrenia between 
first-generation antipsychotic treatment and olanzapine. 
DGDFi is a detailed and length self-report scale with 32 
questions to assess sexual functioning for males and 
41 questions for females in respect to sexual activity 
frequency, desire, arousal and orgasm and perceptions 
of medications side effects in the prior 2 weeks. Unlike 
the more traditional and lengthy scales for assessing 
sexual dysfunctions, the ASEX can be completed in ap-
proximately 5 minutes27, it is a brief 5-item questionnaire 
designed to measure sexual functioning in the following 
domains: sexual drive, arousal, penile erection/vaginal 
lubrification, ability to reach orgasm, and satisfaction 
with orgasm over the past week25 . 
The frequency of sexual dysfunctions was very high, 
a finding consistent with previous studies conducted 
in different countries6,11,15,32-35. Females had a much hi-
gher rate (79.2%) than males (33.3%). Indeed, females 
reported high frequencies of sexual dysfunctions in all 
stages of sexual activities (sexual drive, arousal, vaginal 
lubrification, ability to reach orgasm and satisfaction 
with orgasm). This difference between genders can be 
attributed to biopsychossocial factors, in special: sexual 
hormones (estrogens × androgens), sexual education 
(repressing × permissive), environment (controlling × 
stimulant)36.
Patients under second-generation antipsychotics had 
a higher probability of dysfunction (28.1%) than those 
under first-generation antipsychotics (13.6%). Antip-
sychotic medications were associated to disturbance 
on penile erection and vaginal lubrication reported in 
ASEX questionnaire and had scores ranging progressi-
vely for first-generation antipsychotics (13.6%), second-
generation antipsychotics without risperidone (28.1%), 
risperidone (21.4%), combination of antipsychotics 
(61.5%), or combination of antipsychotics and antide-
pressants (50%).
Although new second-generation antipsychotics 
were expected to be associated with a lower incidence 
of sexual dysfunction as compared with first-generation 
antipsychotic medications37-44, other studies have not 
confirmed these findings6,15,22,30. Increased prolactin 
levels are believed to play a major role in sexually 
induced side effects, but the underlying mechanism 
of antipsychotic agent-induced sexual dysfunction 
remains poorly understood45. Contrary to the fact that 
the causes for sexual dysfunction of antipsychotics 
were exclusively secondary to hyperprolactinemia, is 
that clozapine produced little or no change on serum 
prolactin concentration46, but high rates of sexual side 
effects in a prospective drug monitoring program47. Be-
cause of the scarcity of comparative studies, conflicting 
data and methodological issues, the interpretation of the 
findings of antipsychotics leading to sexual dysfunctions 
are inconclusive2. 
In our study, the pharmacological interventions were 
different between genders: women under long-term 
treatment with antipsychotics, especially with combina-
tions of antipsychotics or antipsychotics and antidepres-
sants, had significantly more sexual dysfunction in the 
items related to sexual drive (p = 0.0131) and orgasm 
(p = 0.0225); men had no significant difference between 
the items when analyzed separately. This difference may 
be explained because women are clearly more sensitive 
than men to the effects of antipsychotics on prolactin48-50. 
In a 6-week study, 63% of haloperidol-treated men, com-
pared with 98% of haloperidol-treated women had a pro-
lactin level above the upper limit of normal48. There are 
few systematic data available regarding the frequency of 
impaired sexual interest or function with antipsychotic 
treatment, and almost all studies are cross-sectional51. 
Although less research on this subject has been con-
ducted in women than in men with schizophrenia, there 
is evidence that sexual and hormonal dysfunction is also 
commom in antipsychotic-treated women. In addition, 
33% of women complained of change in quality of orgasm 
in a cross-sectional study52. One study comparing sexual 
side effects in patients treated with haloperidol and 
clozapine found similar proportions treated with both 
antipsychotics and reported decreased sexual desire 
in 28-33% of women47. Another study examining sexual 
function in women treated with typical antipsychotics 
found a similar proportion (22%), reporting decreased 
ability to achieve orgasm with antipsychotic treatment17. 
There is a need of sexual dysfunction studies including 
women. Many clinical studies have tended to enlist few 
women or have excluded them altogether53. Women may 
underreport the frequency of sexual side effects because 
they are embarassed to discuss this topic. There is a 
naturalistic study of galactorrhea incidence in women 
treated with typical antipsychotics, 20 of 28 women who 
developed galactorrhea failed to spontaneously report 
this side effect on general inquiry by treating physi-
cian about medication side effects54, so it is important 
to develop scales that let women confortable to discuss 
sexuality. 
This study had some limitations that should be con-
sidered when interpreting the data. First, all patients 
were recruited with ages ranging from 20 to 66 years. 
The sexual dysfunction worsens with age since 39% of 
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40-year-olds have some degree of erectile dysfunction 
(5% are completely impotent), but by the age of 70, two 
thirds have some degree of erectile dysfunction and 
complete impotence triples to 15%55. Second, in this 
study there were no exclusion criteria such as comorbid 
depressive syndrome or diabetes, treatment with anti-
depressants, use of alcohol or cigarette smoking, and 
thyroid problems. This is not a longitudinal study, and 
there were no measurements of the effects of the illness 
on sexual functioning prior to medication treatment. 
Since this is a croos-sectional study, sexual dysfunction 
was evaluated at a single time point during the patients’ 
drug therapy and no baseline sexual dysfunction was 
determined; therefore, there was no distinction between 
drug-induced or other causative factors. Because of the 
small sample size it was not possible to draw conclusions 
regarding cause and effects and possible relationship of 
antipsychotic doses. However, it is known that the side 
effects of certain drugs are drug-dependent42.
Schizophrenic patients have a certain level of 
sexual life that cannot be ignored by physicians. When 
patients are stable, they want to maintain their sexual 
life. Because of the high rates of sexual dysfunction, 
psychiatrists should pay more attention and ask specific 
questions about their patients’ sexual life in routine 
clinical practice. Structured scales can be useful to di-
minish the embarrassment and discomfort for patients 
and physicians when this issue is raised. Controlled 
studies should directly inquire about sexual side effects 
and investigate how such side effects alter medication 
compliance and quality of life. The development of reli-
able and valid detailed side effect rating scales for use 
in research trials and in clinical encounters, such as 
the ASEX and DGSFi, should help to further elucidate 
data on sexual side effects53. A study showed that the 
prevalence of sexual dysfunction associated with que-
tiapine or risperidone was 11.7% based on spontaneous 
reports, but increased to 32% when assessed using a 
semi-structured interview34. Thus, use of structured 
scales can yield a higher incidence of sexual dysfunc-
tion. There is a need of studies on multifactorial etiol-
ogy of sexual dysfunction. Studies need to account for 
individual variation in what constitutes normal sexual 
functioning and confounding factors that can affect 
sexual functioning2. These include differences between 
genders, alcohol and tobacco use, relationship difficul-
ties, co-prescribed medications and other clinical or 
psychiatric symptoms. Sexual dysfunctions are differ-
ent between males and females with schizophrenia and 
further research on this area should be conducted to 
clarify this complex subject. This study showed that 
the combination of medications (two or more kinds of 
antipsychotics and antipsychotics and antidepressants) 
leads to high rates of sexual dysfunctions; therefore, 
trying to use antipsychotic in monoterapy or lower 
doses, whenever possible, would be of great benefit to 
the patient in terms of achieving a healthier sexual life. 
Since sexual dysfunction has high prevalence in patients 
with schizophrenia spectrum, psychiatrists’ awareness 
and sensitivity regarding this important side effect and 
choosing the correct treatment would contribute to a 
better quality of life for these patients.
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